


Figure S6: Mean probability of objective response in patients with mMCC (upper panels) or advanced/metastatic UC (lower panels) for weight-based (10 mg/kg Q2W) and flat (800 mg Q2W) dosing with avelumab based on $C_{trough,ss}$ (steady-state population pharmacokinetic model).



Box and whisker plots in (a) all patients with mMCC; (b) patients with mMCC stratified by quartiles of weight; (c) all patients with advanced/metastatic UC; and (d) in patients with advanced/metastatic UC stratified by quartiles of weight. $C_{trough,ss}$, steady-state trough concentration; mMCC, metastatic Merkel cell carcinoma; Q2W, every 2 weeks; UC, urothelial carcinoma.